文献速递流行病学与生物统计临床试验与 GCP

补充维生素D预防急性呼吸道感染:个体参与者数据的系统评价与荟萃分析

Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data.
PubMed 文献 · BMJ · 2017-02-15

该研究纳入25项随机双盲安慰剂对照试验(共11321名参与者,年龄0至95岁),获取10933名参与者的个体数据。补充维生素D总体降低急性呼吸道感染风险(调整比值比0.88,95%置信区间0.81至0.96),每日或每周补充且无负荷剂量者获益更明显,基线25-羟维生素D水平低于25 nmol/L者获益最大。

要点

  • 补充维生素D总体降低急性呼吸道感染风险,调整比值比0.88(95%置信区间0.81至0.96)。
  • 每日或每周补充且无负荷剂量者风险降低(调整比值比0.81,0.72至0.91),有负荷剂量者无保护效应。
  • 基线25-羟维生素D低于25 nmol/L者获益最强(调整比值比0.30,0.17至0.53)。

核心结论

  • 补充维生素D安全且总体可预防急性呼吸道感染。
  • 维生素D严重缺乏者及未接受负荷剂量补充者获益最大。

研究设计与样本

  • 系统评价与个体参与者数据荟萃分析,检索Medline、Embase、Cochrane中央对照试验注册库、Web of Science、ClinicalTrials.gov及国际标准随机对照试验编号注册库,检索时间自建库至2015年12月。
  • 纳入标准为随机、双盲、安慰剂对照的维生素D3或维生素D2补充试验,任何持续时间,需经研究伦理委员会批准,且前瞻性收集急性呼吸道感染发生率并预设为疗效结局。
  • 共纳入25项符合条件的随机对照试验,总计11321名参与者,年龄0至95岁;获得10933名(96.6%)参与者的个体数据。

主要发现

  • 补充维生素D降低所有参与者的急性呼吸道感染风险(调整比值比0.88,95%置信区间0.81至0.96;异质性P<0.001)。
  • 亚组分析中,每日或每周补充且无额外负荷剂量者可见保护效应(调整比值比0.81,0.72至0.91),接受一次或多次负荷剂量者未见保护效应(调整比值比0.97,0.86至1.10;交互作用P=0.05)。
  • 在每日或每周补充维生素D者中,基线25-羟维生素D水平低于25 nmol/L者的保护效应强于基线水平不低于25 nmol/L者(调整比值比0.30,0.17至0.53 vs 0.75,0.60至0.95;交互作用P=0.006)。
  • 维生素D未影响经历至少一次严重不良事件的参与者比例(调整比值比0.98,0.80至1.20,P=0.83)。
  • 贡献于这些分析的整体证据质量被评为高质量。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objectives To assess the overall effect of vitamin D supplementation on risk of acute respiratory tract infection, and to identify factors modifying this effect.Design Systematic review and meta-analysis of individual participant data (IPD) from randomised controlled trials.Data sources Medline, Embase, the Cochrane Central Register of Controlled Trials, Web of Science, ClinicalTrials.gov, and the International Standard Randomised Controlled Trials Number registry from inception to December 2015.Eligibility criteria for study selection Randomised, double blind, placebo controlled trials of supplementation with vitamin D3 or vitamin D2 of any duration were eligible for inclusion if they had been approved by a research ethics committee and if data on incidence of acute respiratory tract infection were collected prospectively and prespecified as an efficacy outcome.Results 25 eligible randomised controlled trials (total 11 321 participants, aged 0 to 95 years) were identified. IPD were obtained for 10 933 (96.6%) participants. Vitamin D supplementation reduced the risk of acute respiratory tract infection among all participants (adjusted odds ratio 0.88, 95% confidence interval 0.81 to 0.96; P for heterogeneity <0.001). In subgroup analysis, protective effects were seen in those receiving daily or weekly vitamin D without additional bolus doses (adjusted odds ratio 0.81, 0.72 to 0.91) but not in those receiving one or more bolus doses (adjusted odds ratio 0.97, 0.86 to 1.10; P for interaction=0.05). Among those receiving daily or weekly vitamin D, protective effects were stronger in those with baseline 25-hydroxyvitamin D levels <25 nmol/L (adjusted odds ratio 0.30, 0.17 to 0.53) than in those with baseline 25-hydroxyvitamin D levels ≥25 nmol/L (adjusted odds ratio 0.75, 0.60 to 0.95; P for interaction=0.006). Vitamin D did not influence the proportion of participants experiencing at least one serious adverse event (adjusted odds ratio 0.98, 0.80 to 1.20, P=0.83). The body of evidence contributing to these analyses was assessed as being of high quality.Conclusions Vitamin D supplementation was safe and it protected against acute respiratory tract infection overall. Patients who were very vitamin D deficient and those not receiving bolus doses experienced the most benefit.Systematic review registration PROSPERO CRD42014013953.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Martineau AR, Jolliffe DA, Hooper RL, et al. Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data. BMJ. 2017. PMID: 28202713. doi:10.1136/bmj.i6583

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。